Richardson BJ Czuppon AB Sharman GB.

Inheritance of glucose-6-phosphate dehydrogenase variation in kangaroos.

Nat New Biol. 230: 154-155Oikawa M Inoue K Shiura H et al.

Understanding the X chromosome inactivation cycle in mice: a comprehensive view provided by nuclear transfer.

Epigenetics. 9: 204-211Patrat C Ouimette JF Rougeulle C.

X chromosome inactivation in human development.

Development. (): 147Petropoulos S Edsgard D Reinius B et al.

Single-cell RNA-seq reveals lineage and X chromosome dynamics in human preimplantation embryos.

Cell. 167: 285

X inactivation, female mosaicism, and sex differences in renal diseases.

J Am Soc Nephrol. 19: 2052-2059Trejo V Derom C Vlietinck R et al.

X chromosome inactivation patterns correlate with fetal-placental anatomy in monozygotic twin pairs: implications for immune relatedness and concordance for autoimmunity.

Mol Med. 1: 62-70Pinto LL Vieira TA Giugliani R Schwartz IV.

Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review.

Orphanet J Rare Dis. 5: 14Tukiainen T Villani AC Yen A et al.

Landscape of X chromosome inactivation across human tissues.

Nature. 550: 244-248Balaton BP Dixon-McDougall T Peeters SB Brown CJ.

The eXceptional nature of the X chromosome.

Hum Mol Genet. 27 ()

X-inactivation and human disease: X-linked dominant male-lethal disorders.

Curr Opin Genet Dev. 16: 254-259

The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family.

J Am Soc Nephrol. 15: 2514-2527

Genetic basis of type IV collagen disorders of the kidney.

Clin J Am Soc Nephrol. 16: 1101-1109Savige J Colville D Rheault M et al.

Alport syndrome in women and girls.

Clin J Am Soc Nephrol. 11: 1713-1720Kashtan CE Ding J Garosi G et al.

Alport syndrome: a unified classification of genetic disorders of collagen IV alpha345: a position paper of the Alport Syndrome Classification Working Group.

Kidney Int. 93: 1045-1051Jais JP Knebelmann B Giatras I et al.

X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males.

J Am Soc Nephrol. 11: 649-657Yamamura T Horinouchi T Nagano C et al.

Genotype-phenotype correlation and the influence of the genotype on response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome.

Kidney Int. 98: 1605-1614

Hereditary familial congenital haemorrhagic nephritis.

Br Med J. 1: 504-506

Familial aspects of diffuse renal diseases.

Annu Rev Med. 15: 115-124Jais JP Knebelmann B Giatras I et al.

X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a “European Community Alport Syndrome Concerted Action” study.

J Am Soc Nephrol. 14: 2603-2610Yamamura T Nozu K Fu XJ et al.

Natural history and genotype-phenotype correlation in female X-linked Alport syndrome.

Kidney Int Rep. 2: 850-855Temme J Peters F Lange K et al.

Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations.

Kidney Int. 81: 779-783Takemon Y Wright V Davenport B et al.

Uncovering modifier genes of X-linked Alport syndrome using a novel multiparent mouse model.

J Am Soc Nephrol. 32: 1961-1973Guo C Van Damme B Vanrenterghem Y Devriendt K Cassiman JJ Marynen P.

Severe Alport phenotype in a woman with two missense mutations in the same COL4A5 gene and preponderant inactivation of the X chromosome carrying the normal allele.

J Clin Invest. 95: 1832-1837Iijima K Nozu K Kamei K et al.

Severe Alport syndrome in a young woman caused by a t(X;1)(q22.3;p36.32) balanced translocation.

Pediatr Nephrol. 25: 2165-2170Rheault MN Kren SM Hartich LA et al.

X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome.

Nephrol Dial Transplant. 25: 764-769Nakanishi K Iijima K Kuroda N et al.

Comparison of alpha5(IV) collagen chain expression in skin with disease severity in women with X-linked Alport syndrome.

J Am Soc Nephrol. 9: 1433-1440Massella L Onetti Muda A Faraggiana T Bette C Renieri A Rizzoni G

Epidermal basement membrane alpha 5(IV) expression in females with Alport syndrome and severity of renal disease.

Kidney Int. 64: 1787-1791Bittel DC Theodoro MF Kibiryeva N Fischer W Talebizadeh Z Butler MG.

Comparison of X-chromosome inactivation patterns in multiple tissues from human females.

J Med Genet. 45: 309-313Wang Y Zhang H Ding J Wang F.

Correlation between mRNA expression level of the mutant COL4A5 gene and phenotypes of XLAS females.

Exp Biol Med (Maywood). 232: 638-642Vetrie D Flinter F Bobrow M Harris A.

X inactivation patterns in females with Alport's syndrome: a means of selecting against a deleterious gene?.

J Med Genet. 29: 663-666

Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020.

Pediatr Nephrol. 36: 711-719Gross O Licht C Anders HJ et al.

Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.

Kidney Int. 81: 494-501

Di H, Zhang J, Gao E, et al. Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome. Nephrol Dial Transplant. Published online January 10, 2022. doi:10.1093/ndt/gfac002.

Stock J Kuenanz J Glonke N et al.

Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations.

Pediatr Nephrol. 32: 131-137Piccoli GB Cabiddu G Attini R et al.

Risk of adverse pregnancy outcomes in women with CKD.

J Am Soc Nephrol. 26: 2011-2022Hladunewich MA Melamed N Bramham K.

Pregnancy across the spectrum of chronic kidney disease.

Kidney Int. 89: 995-1007Blom K Odutayo A Bramham K Hladunewich MA.

Pregnancy and glomerular disease: a systematic review of the literature with management guidelines.

Clin J Am Soc Nephrol. 12: 1862-1872Brunini F Zaina B Gianfreda D et al.

Alport syndrome and pregnancy: a case series and literature review.

Arch Gynecol Obstet. 297: 1421-1431

Women with Alport syndrome: risks and rewards of kidney donation.

Nephrol Dial Transplant. 24: 1369-1370Gross O Weber M Fries JW Muller GA.

Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome: long-term risk, benefit and outcome.

Nephrol Dial Transplant. 24: 1626-1630Hung CL Wu YW Lin CC et al.

2021 TSOC expert consensus on the clinical features, diagnosis, and clinical management of cardiac manifestations of Fabry disease.

Acta Cardiol Sin. 37: 337-354

Fabry's disease.

Lancet. 372: 1427-1435

Precision medicine in Fabry disease.

Nephrol Dial Transplant. 36: 14-23Arends M Wanner C Hughes D et al.

Characterization of classical and nonclassical Fabry disease: a multicenter study.

J Am Soc Nephrol. 28: 1631-1641Wang RY Lelis A Mirocha J Wilcox WR.

Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life.

Genet Med. 9: 34-45Deegan PB Baehner AF Barba Romero MA et al.

Natural history of Fabry disease in females in the Fabry Outcome Survey.

J Med Genet. 43: 347-352Waldek S Patel MR Banikazemi M Lemay R Lee P.

Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.

Genet Med. 11: 790-796Ortiz A Oliveira JP Waldek S et al.

Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.

Nephrol Dial Transplant. 23: 1600-1607Ortiz A Cianciaruso B Cizmarik M et al.

End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.

Nephrol Dial Transplant. 25: 769-775Wilcox WR Oliveira JP Hopkin RJ et al.

Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

Mol Genet Metab. 93: 112-128

Nervous system manifestations of Fabry disease: data from FOS - the Fabry Outcome Survey.

in: Mehta A Beck M Sunder-Plassmann G Fabry Disease: Perspectives From 5 Years of FOS. Oxford PharmaGenesis, Felis A Whitlow M Kraus A Warnock DG Wallace E.

Current and investigational therapeutics for Fabry disease.

Kidney Int Rep. 5: 407-413

Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant).

Best Pract Res Clin Endocrinol Metab. 30: 263-276Kinoshita K Miura Y Nagasaki H Murase T Bando Y Oiso Y.

A novel deletion mutation in the arginine vasopressin receptor 2 gene and skewed X chromosome inactivation in a female patient with congenital nephrogenic diabetes insipidus.

J Endocrinol Invest. 27: 167-170Sasaki S Chiga M Kikuchi E Rai T Uchida S.

Hereditary nephrogenic diabetes insipidus in Japanese patients: analysis of 78 families and report of 22 new mutations in AVPR2 and AQP2.

Clin Exp Nephrol. 17: 338-344van Lieburg AF Verdijk MA Schoute F et al.

Clinical phenotype of nephrogenic diabetes insipidus in females heterozygous for a vasopressin type 2 receptor mutation.

Hum Genet. 96: 70-78Sarafrazi S Daugherty SC Miller N et al.

Novel PHEX gene locus-specific database: comprehensive characterization of vast number of variants associated with X-linked hypophosphatemia (XLH).

Hum Mutat. 43: 143-157Yamamoto A Nakamura T Ohata Y Kubota T Ozono K.

Phenotypes of a family with XLH with a novel PHEX mutation.

Hum Genome Var. 7: 8Quinlan C Guegan K Offiah A et al.

Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment.

Pediatr Nephrol. 27: 581-588Haffner D Emma F Eastwood DM et al.

Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia.

Nat Rev Nephrol. 15: 435-455Morey M Castro-Feijoo L Barreiro J et al.

Genetic diagnosis of X-linked dominant hypophosphatemic rickets in a cohort study: tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation type.

BMC Med Genet. 12: 116Holm IA Nelson AE Robinson BG et al.

Mutational analysis and genotype-phenotype correlation of the PHEX gene in X-linked hypophosphatemic rickets.

J Clin Endocrinol Metab. 86: 3889-3899Gianesello L Del Prete D Anglani F Calo LA.

Genetics and phenotypic heterogeneity of Dent disease: the dark side of the moon.

Hum Genet. 140: 401-421

Dent disease in Chinese children and findings from heterozygous mothers: phenotypic heterogeneity, fetal growth, and 10 novel mutations.

J Pediatr. 174 ()Ye Y Wang J Quan X et al.

Case report: a Chinese girl with dent disease 1 and turner syndrome due to a hemizygous CLCN5 gene mutation and Isochromosome (Xq).

BMC Nephrol. 21: 171Orphanet J Rare Dis. 1: 16De Matteis MA Staiano L Emma F Devuyst O.

The 5-phosphatase OCRL in Lowe syndrome and Dent disease 2.

Nat Rev Nephrol. 13: 455-470Sharma S Skowronek A Erdmann KS.

The role of the Lowe syndrome protein OCRL in the endocytic pathway.

Biol Chem. 396: 1293-1300Festa BP Berquez M Gassama A et al.

OCRL deficiency impairs endolysosomal function in a humanized mouse model for Lowe syndrome and Dent disease.

Hum Mol Genet. 28: 1931-1946

Application of chromosome microarray analysis in patients with unexplained developmental delay/intellectual disability in South China.

Pediatr Neonatol. 60: 35-42Yamamoto K Hasegawa Y Ohata Y et al.

Complete oculocerebrorenal phenotype of Lowe syndrome in a female patient with half reduction of inositol polyphosphate 5-phosphatase.

CEN Case Rep. 9: 95-100